Safety of Continuous Neostigmine for the Treatment of Impaired Gastrointestinal Motility in Pediatric Patients. Ann Pharmacother 2021 Feb;55(2):267-268
Date
07/07/2020
Pubmed ID
32627563DOI
10.1177/1060028020940622Scopus ID
2-s2.0-85087445044 (requires institutional sign-in at Scopus site)
Author List
Cramer J, Pabian I
Author
Jesse L. Cramer PharmD Adjunct Assistant Professor in the School of Pharmacy Administration department at Medical College of Wisconsin